Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 13 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Relay Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 162 | 165 | +3 |
| Shares | 123.5M | 128.1M | +4.64M (+3.8%) |
| Value | $2.76B | $1.91B | −$848.0M (−30.7%) |
New holders (29)
Institutions that held Relay Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (26)
Institutions that held Relay Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.